Coya Therapeutics, Common Stock Today

COYA Stock   6.38  0.12  1.85%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Less than 21

 
High
 
Low
Low
Coya Therapeutics, is trading at 6.38 as of the 27th of November 2024, a 1.85 percent decrease since the beginning of the trading day. The stock's open price was 6.5. Coya Therapeutics, has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Coya Therapeutics, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of December 2022
Category
Healthcare
Classification
Health Care
Coya Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 16.71 M outstanding shares of which 196.52 K shares are currently shorted by private and institutional investors with about 1.5 trading days to cover. More on Coya Therapeutics, Common

Moving together with Coya Stock

  0.62KZR Kezar Life SciencesPairCorr

Moving against Coya Stock

  0.48MTEM Molecular TemplatesPairCorr
  0.47CYRX CryoportPairCorr
  0.41NKTX Nkarta IncPairCorr
  0.39MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.36RNXT RenovoRxPairCorr
  0.35AGL agilon healthPairCorr

Coya Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President OfficerFAPA DO
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.120.13
Significantly Down
Slightly volatile
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
Total Current Liabilities2.9 M5.1 M
Way Down
Slightly volatile
Non Current Liabilities Total546 K574.7 K
Notably Down
Slightly volatile
Total Assets43.3 M41.3 M
Sufficiently Up
Slightly volatile
Total Current Assets43.3 M41.2 M
Sufficiently Up
Slightly volatile
Coya Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Coya Therapeutics,'s financial leverage. It provides some insight into what part of Coya Therapeutics,'s total assets is financed by creditors.
Liquidity
Coya Therapeutics, Common currently holds 5.63 M in liabilities. Note, when we think about Coya Therapeutics,'s use of debt, we should always consider it together with its cash and equity.

Change In Cash

28.03 Million
Coya Therapeutics, Common (COYA) is traded on NASDAQ Exchange in USA. It is located in 5850 San Felipe Street, Houston, TX, United States, 77057 and employs 8 people. Coya Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 108.6 M. Coya Therapeutics, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.71 M outstanding shares of which 196.52 K shares are currently shorted by private and institutional investors with about 1.5 trading days to cover. Coya Therapeutics, generates negative cash flow from operations
Check Coya Therapeutics, Probability Of Bankruptcy
Ownership Allocation
Coya Therapeutics, holds a total of 16.71 Million outstanding shares. Coya Therapeutics, Common shows 7.03 percent of its outstanding shares held by insiders and 19.96 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Coya Ownership Details

Coya Therapeutics, Historical Income Statement

At present, Coya Therapeutics,'s Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 671.3 K, whereas Depreciation And Amortization is forecasted to decline to about 23.4 K. View More Fundamentals

Coya Stock Against Markets

Coya Therapeutics, Corporate Management

When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.65)
Revenue Per Share
0.687
Return On Assets
(0.29)
Return On Equity
(0.51)
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.